Therapeutic Asset Ratings

245 results matching 1 filter

128,359 assets · 8,667 sponsors · 3,127 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Eloxatin substance-related disorder	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Eloxatin First-Line	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Eloxatin Nanoliposomal Irinotecan	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Eloxatin RAS-mutated	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Eloxatin Tislelizumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Epirubicin Pembrolizumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Epirubicin Tumor Thrombosis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Everolimus Targeted Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Famitinib Disitamab Vedotin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Famitinib ERBB2 Gene Duplication	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Famitinib ERBB2 Mutation-Related Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
FILGRASTIM Adolescent	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
FILGRASTIM Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
GLYCIDIDAZOLE Chemoradiotherapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Golidocitinib small cell lung carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER chemotherapy-induced toxicity	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Inetetamab chemotherapy-induced toxicity	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan Cadonilimab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan Capecitabine	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan substance-related disorder	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan First-Line	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan Nanoliposomal Irinotecan	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Irinotecan Oxaliplatin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Ivonescimab Colorectal Liver Metastases	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Mitoxantrone Adolescents	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)

Showing 76 to 100 of 245 assets

PreviousPage 4 of 10Next